Applied Therapeutics Inc. (APLT) Financial Statements (2024 and earlier)

Company Profile

Business Address 545 5TH AVENUE, SUITE 1400
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:30,60080,80096,82938,854
Cash and cash equivalents16,65753,88857,46618,850
Short-term investments 13,92326,93539,36320,004
Other undisclosed cash, cash equivalents, and short-term investments 20(23)  
Receivables23235 
Prepaid expense1702221991,338
Other current assets67447128091
Other undisclosed current assets5,8416,8785,2805,872
Total current assets:37,30888,394102,59346,155
Noncurrent Assets
Operating lease, right-of-use asset8571,2981,7122,035
Other undisclosed noncurrent assets 198200201199
Total noncurrent assets:1,0551,4981,9132,234
TOTAL ASSETS:38,36389,892104,50648,389
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,67513,4484,3289,138
Employee-related liabilities2,7792,103 
Accounts payable4,5349,4616408,793
Accrued liabilities4,1411,2081,585345
Deferred revenue    
Debt    356
Other liabilities481987553264
Other undisclosed current liabilities24,26812,02716,3544,341
Total current liabilities:33,42426,46221,23514,099
Noncurrent Liabilities
Long-term debt and lease obligation:  8911,3321,683
Liabilities, other than long-term debt414   
Operating lease, liability4148911,3321,683
Other undisclosed noncurrent liabilities464(891)(1,332) 
Total noncurrent liabilities:8788911,3321,683
Total liabilities:34,30227,35322,56715,782
Equity
Equity, attributable to parent4,06162,53981,93932,607
Common stock5321
Additional paid in capital352,828328,958242,78099,378
Accumulated other comprehensive income (loss) 51(107)(112)(2)
Accumulated deficit(348,823)(266,315)(160,731)(66,770)
Total equity:4,06162,53981,93932,607
TOTAL LIABILITIES AND EQUITY:38,36389,892104,50648,389

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues    
Gross profit:    
Operating expenses(82,950)(105,618)(94,466)(45,582)
Operating loss:(82,950)(105,618)(94,466)(45,582)
Nonoperating income (expense)4423450569
Other nonoperating expense(177)(521)(54)(24)
Loss from continuing operations:(82,508)(105,584)(93,961)(45,513)
Loss before gain (loss) on sale of properties:(105,584)(93,961)(45,513)
Net loss available to common stockholders, diluted:(82,508)(105,584)(93,961)(45,513)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(82,508)(105,584)(93,961)(45,513)
Other comprehensive income (loss)1585(110)(2)
Comprehensive loss, net of tax, attributable to parent:(82,350)(105,579)(94,071)(45,515)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: